Fulcrum Therapeutics (FULC)
NASDAQ:FULC
Want to see FULC full AI Analyst Report?
FULC Stock Chart & Stats
$8.25
-$0.39(-7.98%)
At close: 4:00 PM EST
$8.25
-$0.39(-7.98%)
Day’s Range― - ―
52-Week Range$2.92 - $15.74
Previous CloseN/A
Volume345.04K
Average Volume (3M)1.09M
Market Cap
$549.45M
Enterprise Value$255.33M
Total Cash (Recent Filing)$352.31M
Total Debt (Recent Filing)$6.44M
Price to Earnings (P/E)―
Beta1.02
Next Earnings
Apr 30, 2026EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.31
Shares Outstanding66,600,210
10 Day Avg. Volume1,084,248
30 Day Avg. Volume1,094,664
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)2.05
Price to Sales (P/S)0.00
P/FCF Ratio-11.87
Enterprise Value/Market Cap0.46
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.35
Forecast
1Y Price Target
$18.86Price Target Upside128.61% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.28
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy SignalsConsistent, dose-related increases in fetal hemoglobin accompanied by fewer painful vaso-occlusive crises indicate pociredir may deliver clinically meaningful benefits that support advancement toward registrational studies.
Regulatory PrecedentAGIO's pursuit of accelerated approval for an SCD therapy establishes a regulatory precedent that could make the FDA more receptive to alternative endpoints in FULC's trial discussions.
Safety And TolerabilityA clean tolerability profile with no treatment-related serious adverse events, no dose-limiting toxicities, and high patient adherence strengthens the case for continued development and regulatory engagement.
Bears Say
Biomarker And Response UncertaintyFlattening improvements in hemolysis markers and lower-than-target proportions of F-cells create doubt about the consistency of biological responses across the patient population.
Headline Metric ShortfallA mean fetal hemoglobin result that fell just below a key round-number benchmark has fueled investor skepticism and contributed to downward pressure on the stock.
Market And Trial Execution RiskReliance on regulatory discretion for trial endpoints and the potential for narrow enrollment criteria could substantially limit the addressable market and leave the stock exposed if future data disappoint.
Fulcrum Therapeutics News
FULC FAQ
What was Fulcrum Therapeutics’s price range in the past 12 months?
Fulcrum Therapeutics lowest stock price was $2.92 and its highest was $15.74 in the past 12 months.
What is Fulcrum Therapeutics’s market cap?
Fulcrum Therapeutics’s market cap is $549.45M.
When is Fulcrum Therapeutics’s upcoming earnings report date?
Fulcrum Therapeutics’s upcoming earnings report date is Apr 30, 2026 which is in 14 days.
How were Fulcrum Therapeutics’s earnings last quarter?
Fulcrum Therapeutics released its earnings results on Feb 24, 2026. The company reported -$0.31 earnings per share for the quarter, missing the consensus estimate of -$0.299 by -$0.011.
Is Fulcrum Therapeutics overvalued?
According to Wall Street analysts Fulcrum Therapeutics’s price is currently Undervalued.
Does Fulcrum Therapeutics pay dividends?
Fulcrum Therapeutics does not currently pay dividends.
What is Fulcrum Therapeutics’s EPS estimate?
Fulcrum Therapeutics’s EPS estimate is -0.29.
How many shares outstanding does Fulcrum Therapeutics have?
Fulcrum Therapeutics has 66,600,210 shares outstanding.
What happened to Fulcrum Therapeutics’s price movement after its last earnings report?
Fulcrum Therapeutics reported an EPS of -$0.31 in its last earnings report, missing expectations of -$0.299. Following the earnings report the stock price went down -21.212%.
Which hedge fund is a major shareholder of Fulcrum Therapeutics?
Currently, no hedge funds are holding shares in FULC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fulcrum Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$18.86 (128.61% Upside)
$18.86 (128.61% Upside)
Blogger Sentiment
Bullish
FULC Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 3.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.8%
Last 30 Days ▲ 4.2%
Last 30 Days ▲ 4.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
170.54%
12-Months-Change
Fundamentals
Return on Equity
-30.25%
Trailing 12-Months
Asset Growth
40.49%
Trailing 12-Months
Company Description
Fulcrum Therapeutics
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
FULC Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a strong set of early biologic and hematologic signals at the 20 mg dose — substantial HbF induction (+12.2% absolute), doubled F-cell percentages, marked reductions in hemolysis markers (LDH -34%, indirect bilirubin -40%), reticulocyte decline (-42%), and a ~1.1 g/dL hemoglobin increase — alongside an acceptable short-term safety profile and a clear regulatory path forward. Major caveats are small sample size, short duration (12 weeks), assay missingness/variability, and that clinical endpoints (VOCs, long-term durability, broader safety) remain exploratory and unproven. On balance the data are encouraging and support advancing to a potential registration-enabling study, while recognizing the need for larger, longer trials to confirm clinical benefit and durability.View all FULC earnings summariesFULC Stock 12 Month Forecast
Average Price Target
$18.86
▲(128.61% Upside)
Technical Analysis
Monopar Therapeutics Inc
―
ADC Therapeutics
―
―
Monte Rosa Therapeutics
―
Inhibrx Biosciences Inc
―
Ownership Overview
10.24% Insiders
7.98% Mutual Funds
59.91% Other Institutional Investors
11.89% Public Companies and
Individual Investors